The interference on insulin signaling and consequent insulin resistance due to the release of IL-6 and TNF-α induced by cancer therapy could also affect liver condition, increasing the risk of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and, in later stages, leading to liver fibrosis/cirrhosis [13,14]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.